Contact lens-based lysozyme detection in tear using a mobile sensor

Supplementary Information

Zachary Ballard^{1,2}, Sarah Bazargan³, Diane Jung³, Shyama Sathianathan³, Ashley Clemens⁴, Daniel Shir^{1,2,3}, Saba Al-Hashimi⁵, and Aydogan Ozcan^{1,2,3,*}

¹Department of Electrical and Computer Engineering, ²California NanoSystems Institute, ³Department of Bioengineering, ⁴Department of Biochemistry, ⁵Stein Eye Institute, University of California, Los Angeles, USA

* Corresponding author: <a>ozcan@ucla.edu



Supplementary Figure

Figure S1. Schematic of the two ends of the optical fiber bundle used for sampling a 96 well-plate. (a) The end of the fiber bundle is directly imaged by the mobile reader. The numbers labeled on each group of three fibers correspond to the well that is sampled by the fibers, as shown in (b). The red arrow indicates the loading direction of the well-plate into the mobile-phone based plate reader.



Figure S2. Contact lens (CL) wear duration versus measured lysozyme concertation using the CL sampling method with Senofilicon A (Acuvue Oasys), Balafilicon A (Pure Vision 2), and Etafilicon A (Acuvue 2) CL materials tested with three human participants.

Supplementary Tables

Table S1. Measured lysozyme levels of the healthy cohort (i.e. no DED) using our CL sampling method and mobile-phone based well-plate reader where each box shows the left (L) and right (R) eye measurement. The monitoring results from six days of measurements over a two-week period where the first five days of monitoring established a monitoring average, culminating in the measurement on the sixth day (Gameday) in which the participants played a game on their mobile-phones during the CL wear duration (15 min). Note: The 'N/A' designates a single measurement day with experimental error in which the standard curve was not properly generated in the well-plate, leading to missing data for either the left or the right eye measurement of participants A, B, G, and H. Note: The 'N/A' for the day 5 measurement (left and right) for participant I designates a no-show on the last measurement day.

					— 5	-Day	Aver	age –				Game	; day 🕇
	Participant ID	DA	Y 1	DA	Y 2	DA	Y 3	DA	Y 4	DA	Y 5	DA	Y 6
		L	R	L	R	L	R	L	R	L	R	L	R
	А	2.65	4.26	2.98	4.01	4.03	5.37	4.79	4.05	4.12	5.08	9.44	19.47
Contact	в	2.33	6.04	4.76	5.16	N/A	5.14	5.32	4.44	4.10	4.18	7.58	7.61
Wearers	с	9.22	10.12	5.10	4.30	7.98	5.98	7.43	4.76	8.77	10.64	11.49	11.81
(CLWs)	D	2.97	10.00	12.24	16.78	8.50	7.38	2.90	6.30	8.94	6.13	15.36	11.82
	Е	15.53	15.65	8.84	10.49	10.66	6.58	9.74	6.01	3.48	4.13	11.62	9.72
	F	7.08	5.92	3.66	4.44	9.64	15.57	5.50	7.18	8.22	10.74	5.72	7.02
	G	10.58	50.18	15.63	11.05	N/A	4.35	12.09	13.79	26.46	14.03	5.66	4.38
Non CLWs	н	5.36	N/A	12.20	6.10	13.33	19.45	5.33	4.06	14.59	9.70	25.11	20.94
	1	32.74	29.42	16.96	7.70	6.08	4.40	4.82	4.13	N/A	N/A	16.88	11.29

Table S2. The DED patient results for the one-time lysozyme measurement using the same procedure	e as
in Table S1, where each box shows the left (L) and right (R) eye measurement.	

ID L R AA 2.73 4.05 BB 0.98 2.02
AA 2.73 4.05 BB 0.98 2.02
BB 0.98 2.02
CC 0.95 0.38
DD 1.58 0.31
EE 2.98 6.87
FF 3.54 2.77